This post was originally published on this site Using veliparib in combination with chemotherapy as first-line and then maintenance therapy post-surgery significantly extended the time without disease progression in women with newly diagnosed metastatic high-grade serous (HGS) ovarian cancer, according to Phase 3 trial results. The research was presented in the session, “VELIA/GOG-3005: Integration of…
This post was originally published on this site Cellectar Biosciences’ investigational radiotherapeutic compound, CLR 131, effectively halted cancer progression and reduced tumor size in people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), interim data of a Phase 2 trial shows. These results were part of the oral presentation “Interim Evaluation of a Targeted Radiotherapeutic, CLR 131,…
This post was originally published on this site Combination therapy with Lenvima (lenvatinib) and Keytruda (pembrolizumab) continues to show promising antitumor results in patients with advanced endometrial cancer, the most common cancer of the uterus, according to the final results of the KEYNOTE-146/Study 111 trial. The combo was generally well-tolerated, and no new safety signals…
This post was originally published on this site Verzenio (abemaciclib) in combination with Faslodex (fulvestrant) prolongs the survival of women with HR-positive, HER2-negative, advanced or metastatic breast cancer who had been treated previously with endocrine therapy, a Phase 3 clinical trial shows. The findings were presented in a late-breaking presentation, “MONARCH 2: Overall survival of…
This post was originally published on this site October is Breast Cancer Awareness Month, but what does that have to do with Alzheimer’s disease and caregiving? Nothing, except that women make up the majority of caregivers in the United States. This means that over 60 percent of caregivers are susceptible to breast cancer. Breast cancer…
This post was originally published on this site The National Institute on Aging (NIA) has awarded a five-year grant expected to total $53.4 million to Brown University and Hebrew SeniorLife to lead the creation and management of a research incubator to test Alzheimer’s and dementia care interventions in real-world settings. Called the NIA Imbedded Pragmatic AD/ADRD Clinical…
This post was originally published on this site Delivering higher doses of radiation therapy over a shorter time period — an approach called stereotactic body radiation therapy (SBRT) — does not worsen side effects in men with localized prostate cancer, compared to conventional radiation therapy, a Phase 3 trial shows. The study also suggests that…
This post was originally published on this site Treatment with Adcetris (brentuximab vedotin) is most effective in people with relapsed or refractory Hodgkin’s lymphoma who have chemotherapy-sensitive disease, and when used as consolidation therapy immediately after stem cell transplant, a study found. The findings were presented at the 2019 European Society for Medical Oncology (ESMO)…
This post was originally published on this site Add-on treatment with Erleada (apalutamide) lowers the risk of death by 25% in men on androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of developing metastases, according to updated results of a Phase 3 trial. The research, “Apalutamide (APA) and Overall…
This post was originally published on this site Leap Therapeutics’s investigational therapy DKN-01, alone or in combination with Taxol (paclitaxel), leads to significantly better responses in women with relapsed endometrial or ovarian cancer whose tumors have high levels of the Dickkopf-1 (DKK1) protein, or specific mutations in the Wnt signaling pathway, according to results of a Phase 2…
